FDA enforcing QbD from 2013 [Dissolution / BCS / IVIVC]

posted by ElMaestro  – Denmark, 2012-01-19 16:19 (5258 d 11:21 ago) – Posting: # 7965
Views: 5,521

Hi all,

I note that FDA has been moving lately in the area of QbD and they seem to be mandating QbD from 2013 for ANDAs / 505(j)'s.
Here's a presentation.

They have even published an example on how it could be done for an MR generic.

I just skimmed through it and I think it is very, very extensive. If this example is in anyway representative of the amount of typically needed from an applicant/developer then I think US development is going to be a lot more expensive in the future.

What's your take on this?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
140 visitors (0 registered, 140 guests [including 25 identified bots]).
Forum time: 04:40 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5